These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30505937)

  • 1. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
    Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
    Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
    Currier MA; Eshun FK; Sholl A; Chernoguz A; Crawford K; Divanovic S; Boon L; Goins WF; Frischer JS; Collins MH; Leddon JL; Baird WH; Haseley A; Streby KA; Wang PY; Hendrickson BW; Brekken RA; Kaur B; Hildeman D; Cripe TP
    Mol Ther; 2013 May; 21(5):1014-23. PubMed ID: 23481323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.
    Klose C; Berchtold S; Schmidt M; Beil J; Smirnow I; Venturelli S; Burkard M; Handgretinger R; Lauer UM
    BMC Cancer; 2019 Dec; 19(1):1172. PubMed ID: 31795974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
    Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
    Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.
    Ringwalt EM; Currier MA; Glaspell AM; Chen CY; Cannon MV; Cam M; Gross AC; Gust M; Wang PY; Boon L; Biederman LE; Schwarz E; Rajappa P; Lee DA; Mardis ER; Carson WE; Roberts RD; Cripe TP
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
    Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
    Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma.
    Jain K; Henrich IC; Quick L; Young R; Mondal S; Oliveira AM; Blobel GA; Chou MM
    Cancer Res Commun; 2023 Aug; 3(8):1615-1627. PubMed ID: 37615015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.
    Studebaker AW; Hutzen BJ; Pierson CR; Haworth KB; Cripe TP; Jackson EM; Leonard JR
    Mol Ther Oncolytics; 2017 Sep; 6():22-30. PubMed ID: 28649600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
    Denton NL; Chen CY; Scott TR; Cripe TP
    Biomedicines; 2016 Jul; 4(3):. PubMed ID: 28536380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
    Currier MA; Sprague L; Rizvi TA; Nartker B; Chen CY; Wang PY; Hutzen BJ; Franczek MR; Patel AV; Chaney KE; Streby KA; Ecsedy JA; Conner J; Ratner N; Cripe TP
    Oncotarget; 2017 Mar; 8(11):17412-17427. PubMed ID: 28147331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.
    Ring EK; Li R; Moore BP; Nan L; Kelly VM; Han X; Beierle EA; Markert JM; Leavenworth JW; Gillespie GY; Friedman GK
    Mol Ther Oncolytics; 2017 Dec; 7():27-36. PubMed ID: 29034313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.
    Zhang W; Hu X; Liang J; Zhu Y; Zeng B; Feng L; Zhao C; Liu S; Liu B; Zhang K
    Mol Ther Oncolytics; 2020 Mar; 16():158-171. PubMed ID: 32055679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation of oncolytic viruses in sarcoma.
    Robinson SI; Rochell RE; Penza V; Naik S
    Mol Ther Oncol; 2024 Sep; 32(3):200822. PubMed ID: 39040851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.
    Leddon JL; Chen CY; Currier MA; Wang PY; Jung FA; Denton NL; Cripe KM; Haworth KB; Arnold MA; Gross AC; Eubank TD; Goins WF; Glorioso JC; Cohen JB; Grandi P; Hildeman DA; Cripe TP
    Mol Ther Oncolytics; 2015; 1():14010. PubMed ID: 27119100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.
    Currier MA; Gillespie RA; Sawtell NM; Mahller YY; Stroup G; Collins MH; Kambara H; Chiocca EA; Cripe TP
    Mol Ther; 2008 May; 16(5):879-85. PubMed ID: 18388918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.
    Yin J; Markert JM; Leavenworth JW
    Front Oncol; 2017; 7():136. PubMed ID: 28695111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.